1 Min Read
Nov 22 (Reuters) - Immunovaccine Inc :
* The european medicines agency grants orphan drug designation status to Immunovaccine’s DPX-Survivac in ovarian cancer Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.